metaEvidence - overview


			deaths (OS)
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	atezolizumab alone vs. gemcitabine plus platin	1	356 [-356; 1067] /10000 191/360 vs. 198/400
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	1	-605 [-1178; -32] /10000 324/467 vs. 350/464
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	2	-546 [-1246; 154] /10000 220/316 vs. 232/309
mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population
mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive
MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population
versus no additional treatment
	atezolizumab alone vs. no additional treatment	1	-
MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive